华西医学

华西医学

纤维蛋白原对冠状动脉粥样硬化性心脏病影响的研究进展

查看全文

冠状动脉粥样硬化性心脏病(冠心病)发病率高,预后差。纤维蛋白原(fibrinogen,Fib)既是凝血因子又是炎症因子,对冠心病发生、发展的各阶段均具有重要的影响。既往研究报道了 Fib 与高血压、糖尿病等冠心病传统危险因素存在普遍相关性,与左心室肥厚等亚临床病变具有正相关性。随着 Fib 水平的升高,人群冠心病发病率逐渐升高,冠心病患者较健康人群具有更高的 Fib 水平,高 Fib 水平的冠心病患者冠状动脉狭窄程度更重,病变范围更广。但 Fib 对冠心病二级预防的影响还存在普遍争议。基于最近对 Fib 在冠心病中的新认识,该文就 Fib 对冠心病影响的研究进展进行了综述。

The morbidity of coronary heart disease (CHD) is high, and the prognosis is unfavorable. Fibrinogen is both coagulation and inflammation factor, which has important influence on the occurrence and development of CHD. Previous studies reported that fibrinogen had relevance with traditional risk factors of CHD such as hypertension, diabetes and subclinical diseases such as left ventricular hypertrophy. The incidence of CHD increases with the fibrinogen level increasing. The fibrinogen level is higher in patients with CHD than that in healthy people. The coronary stenosis degree is heavier and the lesion is wider in patients with hyperfibrinogenemia. But the effects of fibrinogen on the secondary prevention of CHD is controversial. This paper summarized research progress based on the new understanding to fibrinogen on CHD recently.

关键词: 冠状动脉粥样硬化性心脏病; 纤维蛋白原; 预后

Key words: Coronary heart disease; Fibrinogen; Prognosis

引用本文: 刘瑞双, 陈茂. 纤维蛋白原对冠状动脉粥样硬化性心脏病影响的研究进展. 华西医学, 2018, 33(3): 342-347. doi: 10.7507/1002-0179.201706239 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Takarada S, Imanishi T, Ishibashi K, et al. The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv, 2010, 3(7): 766-772.
2. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM, 2003, 96(10): 711-729.
3. Losner S, Volk BW, Wilensky ND. Fibrinogen concentration in acute myocardial infarction-comparison of the clot density determination of fibrinogen with the erythrocyte sedimentation rate. AMA Arch Intern Med, 1954, 93(2): 231-245.
4. Heinrich J, Schulte H, Schönfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost, 1995, 73(3): 374-379.
5. Montalescot G, Collet JP, Choussat R, et al. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J, 1998, 19(Suppl H): H11-H17.
6. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem, 1999, 274(32): 22862-22870.
7. Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem, 1990, 265(11): 6389-6393.
8. Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA, 1987, 258(9): 1183-1186.
9. Eto K, Ochiai M, Isshiki T, et al. Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction. Jpn Circ J, 2001, 65(4): 279-282.